Premium
Prognostic role of insulin‐like growth factor receptor‐1 expression in small cell lung cancer
Author(s) -
CHANG MYUNG HEE,
LEE JEEYUN,
HAN JOUNGHO,
PARK YEON HEE,
AHN JIN SEOK,
PARK KEUNCHIL,
AHN MYUNGJU
Publication year - 2009
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1600-0463.2009.02545.x
Subject(s) - insulin like growth factor 1 receptor , medicine , insulin like growth factor , oncology , insulin like growth factor receptor , lung cancer , growth factor , receptor , immunohistochemistry , receptor expression , endocrinology , pathology
Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K, Ahn M‐J. Prognostic role of insulin‐like growth factor receptor‐1 expression in small cell lung cancer. APMIS 2009; 117: 861–9. Insulin‐like growth factor receptor‐1 (IGFR‐1) is a cellular membrane receptor which is overexpressed in many tumors and seems to play a critical role in anti‐apoptosis. The insulin‐like growth factor binding protein‐3 (IGFBP‐3) is known as a growth suppressor in multiple signaling pathways. The aim of this study was to determine IGFR‐1 and IGFBP‐3 expression in small‐cell lung cancer (SCLC) and analyze the prognostic value in patients with SCLC. We analyzed IGFR‐1 and IGFBP‐3 expression in 194 SCLC tissues by immunohistochemical staining. Correlative analyses between IGFR‐1 and IGFBP‐3 expression in SCLC and clinicopathologic factors were performed. A total of 117 patients had extensive disease (ED) (60.3%) and 77 had limited disease (39.7%). With the median follow‐up duration of 49.5 months (24–82 months), the median progression‐free survival (PFS) and overall survival (OS) were 7.2 months [95% confidence interval (CI): 6.4–8.0 months] and 14.4 months (95% CI: 12.7–16 months), respectively. IGFR‐1 expression was observed in 154 of the 190 tumor tissues, whereas there was no IGFBP‐3 expression. Multivariate analysis showed that stage (p < 0.001), response rate (p < 0.001), and lactate dehydrogenase (LDH) levels (p < 0.001) were the independent prognostic factors for PFS, and age (p = 0.014), LDH level (p < 0.001), and stage (p < 0.001) for OS. The IGFR‐1 positivity was not associated with PFS or OS in the entire cohort. Subgroup analysis revealed that OS was significantly longer in patients with IGFR‐1‐positive tissue than IGFR‐1‐negative tissue in SCLC‐ED (p = 0.034). These results suggest that IGFR‐1 expression may be useful as a prognostic marker in patients with SCLC‐ED.